Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Zenyaku Kogyo.

    Client Virtual Booth

    ZENYAKU KOGYO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Zenyaku Kogyo
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    5-6-15 Otsuka, Bunkyo-ku, Tokyo
    Telephone
    Telephone
    03-3946-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.zenyaku.co.jp/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Anti-CD20 Monoclonal Antibody Rituxan® Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies

    Details:

    Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.


    Lead Product(s): Rituximab

    Therapeutic Area: Nephrology Product Name: Rituxan

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Chugai Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

    Details:

    Under the agreement, Zenyaku gains exclusive rights to develop and commercialize ASLAN004 (eblasakimab), a potential first-in-class monoclonal antibody targeting the IL‑13 receptor subunit, in atopic dermatitis (AD) and all other indications in Japan.


    Lead Product(s): Eblasakimab

    Therapeutic Area: Dermatology Product Name: ASLAN004

    Highest Development Status: Phase IIProduct Type: Large molecule

    Recipient: ASLAN Pharmaceuticals

    Deal Size: $138.5 million Upfront Cash: $12.0 million

    Deal Type: Licensing Agreement June 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention of Recurrence of Neuromyelitis Optica Spectrum Disorder

    Details:

    Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding stem cells and plasma cells. It attacks target B cells using the immune system equipped with the human body, and damages cells.


    Lead Product(s): Rituximab

    Therapeutic Area: Rare Diseases and Disorders Product Name: Rituxan

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Chugai Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus

    Details:

    Rituxan, an anti-CD20 monoclonal antibody got approval in additional indications of refractory pemphigus vulgaris and pemphigus foliaceus by MHLW based on results of investigator-initiated phase II clinical trial in Japan of KCTR-D006 study and PEMPHIX study.


    Lead Product(s): Rituximab

    Therapeutic Area: Immunology Product Name: Rituxan

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Chugai Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 24, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search